Table 1.
Patient characteristics
| Patient characteristic | All patients (n=405) |
|---|---|
| Female, n (%) | 295 (72.8) |
| Age ≥65 years, n (%) | 78 (19.3) |
| Race/ethnicity, n (%) | |
| Caucasian | 338 (83.5) |
| African–American/black | 32 (7.9) |
| Hispanic | 21 (5.2) |
| Unknown | 3 (0.7) |
| Household employment and educational status, n (%) | |
| Employed | 229 (56.5) |
| Unemployed | 176 (43.5) |
| Household income >$75,000 | 206 (50.9) |
| College graduates | 205 (50.6) |
| Type of insurance, n (%) | |
| Commercial | 276 (68.1) |
| Medicare | 108 (26.7) |
| Other | 21 (5.2) |
| Perceived health status, n (%) | |
| Very good/excellent (top 2 ratings) | 98 (24.2) |
| Diagnosed conditions, n (%) | |
| Rheumatoid arthritis | 204 (50.4) |
| Crohn’s disease | 145 (35.8) |
| Ulcerative colitis | 62 (15.3) |
| Psoriasis | 47 (11.6) |
| Psoriatic arthritis | 41 (10.1) |
| Ankylosing spondylitis | 9 (2.2) |
| Non-autoimmune comorbid conditions, n (%) | |
| Hypertension | 104 (25.7) |
| Gastrointestinal problems | 24 (5.9) |
| Fibromyalgia | 20 (4.9) |
| Depression | 18 (4.4) |
| Osteoarthritis | 14 (3.5) |
| Other | 220 (54.3) |
| None | 148 (36.5) |
| Current IV biologic used, n (%) | |
| Infliximab | 332 (82.0) |
| Abatacept | 50 (12.3) |
| Rituximab | 19 (4.7) |
| Other (tocilizumab and vedolizumab) | 4 (1.0) |
| Unknown | 10 (2.5) |
| Prior experience with an SC therapy, n (%) | 150 (37.0) |
| Duration of IV biologic treatment, n (%) | |
| <1 year | 81 (20.0) |
| 1–2 years | 118 (29.1) |
| 3–5 years | 87 (21.5) |
| >5 years | 119 (29.4) |
| Infusion services, n (%) | |
| Rheumatology | 154 (38.0) |
| Gastroenterology | 102 (25.2) |
| Hospital outpatient department | 111 (27.4) |
| Infusion therapy provider | 25 (6.2) |
| Other physician’s office | 6 (1.5) |
| Other | 7 (1.7) |
| Satisfaction with IV biologica | |
| Patients giving top-two ratings (≥6), n (%) | 310 (76.5) |
| Mean rating | 6.1 |
Note:
a
1= not at all satisfied and 7= extremely satisfied.
Abbreviations: IV, intravenous; SC, subcutaneous.